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Abstract
Breast cancer is the most common form of cancer in women. Breast cancer 
has a heterogeneous etiology. Genetic and environmental factors contribute to 
the pathogenesis and progression of breast cancer. Various genes as proliferation 
and nuclear factors have been identified in breast cancer. Therefore, the genetic 
component of patients is important in determining disease behavior, response to 
anticancer therapeutics, and patient survival. Prognosis of breast cancer is associ-
ated with potential metastatic properties of primary breast tumors. Metastasis is 
the leading cause of death in patients with breast cancer. Therefore, it is important 
to understand the mechanisms underlying the development of distant metastases 
to specific regions and has clinical value. Metastasis shows an organ-specific spread 
pattern and occurs with a series of complex and multistep events associated with 
each other, such as angiogenesis, invasion, migration-motility, extravasation, and 
proliferation. Breast cancer often metastasizes to the bone, liver, brain, and lungs. 
Metastasis may develop years after successful primary treatment. The metastatic 
process will become clear, as information about molecules and genes associated 
with metastases increases, and this is extremely important for cancer treatment.
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1. Introduction
Breast cancer, which is one of the most common malignant diseases of women 
worldwide, is a heterogeneous disease with unknown pathogenesis. Genetic and 
environmental factors contribute to the pathogenesis and progression of breast 
cancer. Although an improvement has recently been detected in the diagnosis and 
treatment of breast cancer compared with other cancers, its contribution to survival 
was inadequate.
Breast cancer-associated death or survival is associated with the potential 
metastatic features of the primary breast tumors. Metastatic disease is the leading 
cause of death in breast cancer patients. Distant metastasis develops in ~20–30% 
of the early-stage breast cancer patients. Approximately 90% of deaths result from 
the complications due to recurrent or metastatic diseases. Therefore, it is very 
important to understand the underlying mechanisms in the development of distant 
metastases to specific regions. Metastases may show an organ-specific dissemina-
tion pattern. Metastasis may develop years after successful primary treatment. 
Metastasis frequently develops in the bone, liver, brain, and lungs in breast cancer.
Identification of the molecules, and genes associated with metastasis, and clari-
fication of the contribution of these molecules to metastatic process are important 
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for the treatment of cancer. Metastasis is the dissemination of the cancer cells from 
their primary region to different tissues and organs in the body. Metastasis develops 
with a series of complex and multistep chains of events such as angiogenesis, inva-
sion, migration-motility, extravasation, and proliferation.
The anomalies of different genes as BRCA1, BRCA2, MYC, TP53, RB1, JUN, 
and CDK2A which have roles in cell proliferation are detected in breast cancer [1]. 
Therefore, performing the genetic and molecular screenings of patients is impor-
tant for the identification of the behavior of disease, the anticancer therapeutic 
response, and the survival.
Different breast cancer cellular subtypes in primary breast cancer tissue metas-
tasize in relation to their target organ. The route of metastasis is generated with the 
interaction of this different subtype cells and microenvironment of the tumor and 
with the organ they will locate, and this is named as “organotrophic metastasis.”
Understanding the molecular mechanism of organotrophic metastasis is very 
important for biological indicator prediction, developing the innovative thera-
peutic strategies, and for improving the survival. Development of metastasis in 
distant regions is associated with the interaction between the tumor cells and host 
microenvironment. Before the initiation of tumor dissemination, the host micro-
environment is modified to support the tumoral growth, in other words to create 
a pre-metastatic niche (PMN). PMN is organized with the factors secreted from 
tumor cell with the changes in the host cell metabolism and microenvironment. In 
addition, tumor cells also interact with the extracellular matrix (ECM) of the host 
tissue to facilitate metastasis.
Generally, breast cancer is classified as in situ carcinoma and invasive carcinoma 
in a simple way, and most breast cancers are invasive. More than 80% of invasive 
breast cancers may be investigated in two different subgroups as invasive ductal 
carcinoma (IDC), and some breast cancers may be investigated as invasive lobular 
carcinoma (ILC). Organ preference of metastasis in ILC and IDC is significantly 
distinct. Invasive ductal carcinomas do metastasis to the lungs, distant lymphatic 
glands, and central nervous system (CNS); however, ILC is known to do threefold 
higher metastasis to the peritone, gastrointestinal system, and ovaries [2].
Breast cancer has a tendency to do metastasis on the bone, liver, lung, and 
distant lymphatic glands. The most common metastasis type is the bone metastases 
detected in 70% of metastatic breast cancer patients [1]. The second most common 
metastasis region was the liver with ~30%, and the brain was reported as the third 
most common metastasis region with a rate of 10–30% [1].
The most common metastatic region in all subtypes except basal-like tumors is the 
bone. Luminal B, HER2+/ER/PR+ and HER2+/ER/PR, tumors do more metastasis to 
the brain, liver, lungs, and bone than the luminal A tumors. Basal-like tumors do higher 
rates of the brain, lungs, and distant lymphatic node metastasis; however, the liver and 
bone metastases are less frequently detected in basal-like tumors [3]. Although triple 
negative breast cancer (TNBC) tumors show a metastatic ratio similar to non-basal 
tumors, TNBC tumors have less liver metastasis than the non-basal tumors [1].
Some molecules may have different roles in different metastasis regions in 
accordance with their content. Although transforming growth factor beta (TGF-β) 
promotes the lung metastasis of breast cancer, its interaction with Src signaling 
pathway may cause bone metastasis [4]. In cancer cells with insulin-like growth 
factor (IGF1) and IGF1 receptor (IGF1R), bone metastasis shows higher expression 
than the cancer cells with brain metastasis [5]. EGFR ligands and cyclooxygenase 
2 (COX2) were reported to be associated with lung metastasis and, however, were 
reported to be not associated with bone or liver metastasis [6].
Wnt-1-inducible-signaling pathway protein1 (WISP-1) and CCN4 are heparin-
binding glycoproteins of the CCN protein family that are rich in cysteine. These 
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proteins are expressed in various inner organs such as the lung, kidney, and spleen. 
WISP-1 binds to BMP-2 and increases the mesenchymal cellular proliferation 
and osteoblastic differentiation. WISP-1 was reported to be associated with the 
increased metastasis risk among early-stage ER-positive lymphatic node-negative 
breast cancer patients [7]. Therefore, future studies will demonstrate whether 
genetic factors associated with WISP-1 and EXT1 genes may show metastasis risk 
or may be used in identification of metastasis. In addition, the increase of WISP-1 
expression was proven to be associated with the pathogenesis of the primary lung 
cancers. Although the possibility of WISP-1 to be used as a prognostic indicator 
for lung metastasis of breast cancer was suggested, it was not clarified yet whether 
WISP-1 was a tumor stimulant or a tumor suppressor.
Breast cancer cells are detected to highly express the chemokine receptors 
CXCR4 and CCR7 genes in the studies investigating the contribution of chemo-
kine receptors to organ-specific metastases. Chemokine receptor-specific ligands 
CXCL12 and CCL21 were demonstrated to be highly expressed in the organs to 
which breast tumors do metastasis such as the lymph nodes, lungs, liver, and bone 
marrow [8]. In addition, the blockade of CXCR4 gene in experimental animal mod-
els was demonstrated to inhibit the metastasis of breast cancer cells. The activation 
of the RAS/mitogen-activated protein kinase (MAPK) with chemokine signaling 
pathway causes changes in primary cancer cells such as changes in the intracellular 
actin molecule polymerization, development of pseudopodia, and increased cellular 
motility, cellular migration, and tissue invasion. Any of these changes contribute 
to the development of organ-specific metastasis by contributing to the survival, 
metastasis, and vitality ability of cancer cells.
2. Metastasis-associated signal transduction pathways and genes
2.1 p38/MAPK pathway
p38/MAPK signal transduction pathway increases the breast carcinoma vas-
cularization and growth by promoting the expression and accumulation of pro-
tumorigenic factors.
The inactivation of the p38/MAPK signaling pathway was provided by the expres-
sion of the kinase-inactive mutant (dn-p38) of p38/MAPK14 in metastatic breast 
cancer cells in the studies, and with the deterioration of the tumor p38/MAPK signal, 
the development of breast cancer and metastasis ability was shown to decrease in 
breast carcinoma xenografts [9]. The conducted kinase-inactive mutant significantly 
decreased the dn-p38, tumor blood vessel density, and lumen dimensions. p38 con-
trols the expression of the pro-angiogenic extracellular factors such as matrix protein 
fibronectin, cytokine, vascular endothelial growth factor A (VEGFA), and IL8. p38/
MAPK signal transduction was demonstrated to increase the tumoral growth, and 
vascularization in addition to increasing the expressions of tumor-associated fibro-
blasts, and pro-angiogenic factors. All these effects were suppressed by the dn-p38 
kinase-inactive mutant. The data analyses showed that p38 had higher expression in 
breast cancers which was an indicator of recurrence and poor prognosis. The activa-
tion of the p38/MAPK signaling pathway in the tumor increased the development of 
breast cancer and metastasis. p38 contributes to the vascularization of carcinoma by 
facilitating the expression and accumulation of the pro-angiogenic factors. In conclu-
sion, all these results suggested that all the genes which have a role in p38/MAPK 
pathway might be a therapeutic target against tumor vascularization and metastasis.
Tumor microenvironment (TME) is an important factor in cancer progres-
sion, recurrence, and response to treatment. TME blood vessels consist of stromal 
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cells (fibroblasts, adipocytes) and infiltrating immune cells. Myeloid cells stimu-
late the tumor vascularization and metastasis by secreting metalloproteinase 
MMP9/gelatinase-B cells which increase the gathering of endothelial cells and peri-
cytes. In addition to myeloid cells, MMP9 is also produced by the breast carcinoma 
cells, and the MMP9 destruction in carcinoma cells significantly decreases tumor 
vascularization [10]. Therefore, all three cellular components of the TME of breast 
contribute to the tumor vascularization by interacting with MMP9. p38/MAPK 
signal contributes to the development of breast cancer and metastasis by increasing 
the tumor cell invasiveness and tumor vascularization.
MMP9 that has a role in tumor angiogenesis and intratumoral vascularization-
associated ICAM1 works correlated with p38/MAPK signal. ICAM1 is also suggested 
as a target in triple negative breast cancer (TNBC) [11]. The inhibition of p38/
MAPK signal affects the TNF-induced ICAM1 expression or the induction of MMP9 
by the cytokines TGF-β and TNF.
The deterioration of p38/MAPK signal causes no decrease in the expression of 
MMP9 and ICAM1 that are secreted by tumor cells. p38/MAPK signal contributes 
to fibronectin expression by responding to cytokines and tumor-fibroblast interac-
tions [9].
p38/MAPK induces the expression of pro-angiogenic cytokines that include 
VEGFA, IL8, and HBEGF in addition to inducing an extracellular matrix protein 
fibronectin. TAK1 controls the expression of MMP9 which releases VEGF and 
activates the IL8 (Figure 1). Pro-angiogenic cytokines increase the tumoral growth 
by stimulating the tumoral vascularization.
p38/MAPK affects the development and metastasis of breast cancer by changing 
the tumor microenvironment of p38/MAPK signal. The inactivation of p38/MAPK 
signal in breast cancer cells decreases the growth of tumor xenografts and metastasis. 
Tumoral and stromal cells in breast TME stimulate the cytokine-mediated p38/
MAPK signal which increases the expression of the pro-angiogenic and pro-invasive 
factors such as VEGFA, IL8, IL6, HBEGF, and fibronectin. p38/MAPK which affects 
Figure 1. 
The role of p38/MAPK in the regulation of tumor angiogenesis in breast cancer.
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the vascular structure and stroma of tumor is detected to be definitely a potential 
target for anticancer treatment. Researchers suggested that anti-p38 drugs were a new 
therapeutic option in the treatment of breast cancer including metastatic disease [9].
2.2 Tumor endothelial marker 8 (TEM8)
Tumor endothelial marker (TEM8) was first discovered in the human tumor 
endothelial and was associated with tumor angiogenesis. TEM8 also known as 
Anthrax toxin receptor 1 (ANTXR1) is highly regulated in tumor endothelial and 
is expressed in breast cancer. TEM8 was demonstrated to be required for tumoral 
growth and angiogenesis [12]. The role of TEM8 in angiogenesis is organized 
with the regulation of downstream VEGF signal with its interaction with vascular 
endothelial growth factor receptor 2 (VEGFR2). Primary tumor development and 
metastasis are highly dependent on angiogenesis. Because the tumor cannot grow 
more than a few millimeters unless new blood vessels that will provide the oxygen 
and nutrients to tumor tissue are generated. The extravasation and dissemination 
of metastatic cells out of the vessel are facilitated and accelerated due to the leaky 
structure of the rapid developing tumor vessel network during tumor angiogen-
esis. Therefore, treatments targeting TEM8 can differentiate the physiologic and 
pathological angiogenesis and can prevent the cancer progression without causing 
serious adverse effects. Due to this feature, TEM8 is suggested to be a new possible 
therapeutic target in inhibiting the metastasis.
The destruction of TEM8 in osteosarcoma cells causes the decrease of the cell 
proliferation [13]. TEM8 interacts with the lipoprotein receptor associated protein 
6 (LRP6) and regulates the downstream signaling of Wnt which is a protein that 
induces both the cellular proliferation and migration. TEM8 was reported to regu-
late metastasis and a new molecule specific for metastasis by contributing the breast 
cancer stem cells (BCSC) and tumor growth with activating the Wnt signal with col-
lagen VI [14]. TEM8 is associated with invasive and aggressive phenotype in breast 
cancer. In addition, TEM8 expression was demonstrated to be highly expressed in 
the tumor tissues of breast cancer patients compared to the normal tissues [14].
TEM8 expressed by cancer cells causes the development of angiogenesis by 
affecting the cancer cell proliferation and endothelial cell migration. TEM8 
knockout (KO) cells were generated using CRISPR/Cas9, TEM8 expression was 
demonstrated to significantly disappear, and TEM8 was inhibited in the studies 
investigating the association of TEM8 with metastasis (Figure 2). Thus, angio-
genesis decreased in tumor cells, and metastasis ability of TEM8 significantly 
Figure 2. 
The effect of TEM8 in breast cancer metastasis.
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degraded with the deletion in cancer cells. Cancer cell proliferation, angiogenesis, 
and metastases are blocked with the prevention of cell cycle and the expression of 
the kinetochore-associated genes with the inhibition of TEM [15]. Cancer cells are 
known to secrete the pro-angiogenic signals such as VEGFA and open the angio-
genic lock by affecting the tumor microenvironment. TEM8 is known to work in 
cooperation with other factors such as VEGF for promoting endothelial cell migra-
tion and angiogenesis. In conclusion, TEM8 expression is higher in tumor cells 
than in normal cells. Studies conducted using TEM8 knockout metastatic breast 
cancer cell lines designed with CRISPR/Cas9 emphasize the role of TEM8 in cancer 
development, tumor angiogenesis, and local metastasis. All these studies reveal the 
potential of TEM8 as a therapeutic target for combating the disease; however, more 
clinical studies are required for developing the TEM8-targeted therapies [15].
2.3 APOBEC3B gene
Another important molecule in the development of metastatic potential of breast 
cancer is APOBEC3B. High level of APOBEC3B mRNA expression was demonstrated 
to be a significant prognostic biological indicator demonstrating the poor prognosis 
of breast cancer in ER-positive primary breast cancer cases. In addition, this molecule 
in distant metastasis regions was demonstrated to be highly expressed than the levels 
in regional lymph node metastases. This showed that APOBEC3B not only in the 
primary tumor stage has a role in the development of different metastatic stages of 
breast cancer. In conclusion, APOBEC3B causes the progression of metastatic breast 
cancer [16]. Therefore, the identification of different expression levels of APOBEC3B 
suggests that it carries a biological marker feature that may show a different meta-
static stage and may be used in the identification of the metastasis stages in future.
3. Metastasis of breast cancer to different organs
3.1 Lymph node metastasis
Lymph node metastasis shows that distant metastasis risk is higher. The absence 
of lymph node metastases is associated with lower metastasis risk; however, the 
presence of more than four lymph node metastases is the precursor that distant 
metastasis risk is significantly higher. Distant tumor metastasis develops through 
axillary lymphoid nodes (ALD) and blood circulation. Therefore, lymph nodes are 
used as an indicator of the metastasis ability of tumor cells. There is an association 
between the tumor size and the rate of lymph node metastasis.
CCN proteins which have oncogenic functions in breast cancer mainly consist 
of CCN1 and CCN2. CCN1 protein is expressed in ~30% of breast cancers particu-
larly in estrogen receptor (ER)-positive HER-2-negative tumors compared with 
the normal breast tissues. Higher CCN1 expression is associated with lymph node 
metastasis and poor prognosis in breast cancer patients. CCN1 increases the breast 
tumor vascularization and causes metastasis with Hg signaling [17]. In addition, 
CCN1 has a regulatory role in fibroblast production by affecting MMP-1 for increas-
ing the breast cancer cell migration and invasion. CCN4 expression is associated 
with lymph node metastasis and poor prognosis.
3.2 Bone metastasis
The common cause of morbidity and mortality in most advanced stage breast 
cancer patients is the development of osteolytic bone metastasis. The most 
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frequently detected area of metastasis in metastatic breast cancer is the bone and 
constitutes 70% of the metastases. Most bone metastases detected in breast cancer 
are associated with osteolytic-type metastatic lesions owing to the osteoclast-medi-
ated bone resorption. Although all subtypes of breast cancer have a tendency of 
bone metastases, luminal subtype tumors develop higher bone metastases (80.5%) 
than the basal-like (41.7%) and HER2+ tumors (55.6%) [18].
Tumor cells demonstrate different reactions in accordance with the environment 
in the new organ such as gene expression, growth ability, and response to treat-
ment. Therefore, any of the breast cancer cell reaching to the bone may promote 
the excessive growth in molecular interaction with osteoblasts and osteoclasts. The 
molecules produced by cancer cells or with the parathyroid hormone-associated 
protein in the bone microenvironment and converting growth factor β (TGF-β) 
mediate this growth. The elimination of the tumor suppressor feature of TGF-β is 
suggested to stimulate the tumor invasion and metastasis [19]. Cytokines, che-
mokines, and other growth factors support the development of bone metastasis. 
Prometastatic cytokine TGF-β, osteolytic angiogenic factors interleukin-11 (IL11), 
and CTGF expression are accepted as the molecules that increase the osteolytic 
metastatic activity. Although SMAD4 is a tumor suppressor which inhibits the 
tumor cell proliferation, it is an osteolytic metastasis promoter which binds the 
TGF-β signal to the following IL11 induction [20]. SMAD4 activates VEGF and 
CXC chemokine receptor 4 (CXCR4) to induce the bone metastasis in breast cancer 
through HIF-lα and TGF-β signal.
Some cancer cells in the primary tumor accumulate additional genetic changes 
which lead to bone metastasis. This causes invasion and colonization of tumor cells 
to the bone matrix. The destruction of the bone matrix with tumor cells facilitates 
the metastasis by the TGF and metastasis genes responding to TGF causing the 
increase of CTGF and IL11 expression. IL11, CTGF, CXCR4, and MMP-1 are the 
four most effective genes that are overexpressed in bone metastasis. Another 
effective gene is the protein osteopontin (OPN) which has various functions 
including the stimulating ability of the bone matrix to attach to the osteoclast. 
This protein is continuously overexpressed in metastatic cells. The genes effective 
in bone metastasis affect the tumor microenvironment toward metastasis. The 
overexpression of these genes develops the osteolytic bone metastasis. IL11 is a 
strong osteoclast inducer which is synthesized by the progenitor cells in the bone 
marrow [17]. The in vivo testing of IL11-transfected MDA-MB-231 for metastatic 
activity of metastatic breast cancer cell line showed that the single expression of 
IL11 did not significantly increase the metastasis. Therefore the presence of other 
genes in cooperation with IL11 in bone metastasis and their investigation were 
suggested [17]. IL11 and OPN significantly increased the osteolytic bone metastasis 
by increasing the osteoclast function. MMP-1 alone or in combination with IL11 and 
OPN is another important molecule in the development of bone metastasis.
Because TGF-β is abundantly stored in the bone matrix, TGF-β that is secreted 
during osteolysis stimulates the metastatic breast cancer. TGF-β increases the IL11 
and CTGF expressions which are already higher in metastasis. The significantly 
overexpressed genes in bone metastasis encode the cell surface and secreting pro-
teins which have functions that could possibly change the host tissue environment, 
each promoting the formation of osteolytic bone lesions.
Figure 3 demonstrates the functioning between the CXCR4 gene responsible in 
bone marrow extravasation, MMP-1 and ADAMTS1 genes having roles of proteoly-
sis and also FGF5 and CTGF genes that are known to be expressed in angiogenesis, 
and IL11 genes which have a role in osteoclastogenesis.
Primary breast tumor develops with the accumulation of oncogenic mutations 
from normal breast epithelium. The increased expression of gene classes that 
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facilitate metastasis to different organs among tumor cells enables the invasion 
of the bone matrix, colonization of metastatic tumor cell, and destruction of the 
bone matrix [21].
CCN protein family consists of six members as CCN1 (Cyr61), CCN2 (CTGF), 
CCN3 (Nov), CCN4 (WISP-1), CCN5 (WISP2), and CCN6 (WISP3) which have 
central roles in development, inflammation, and tissue repair [22]. In addition, 
CCN proteins have roles in various pathological cases by organizing the extracel-
lular signals in the cellular environment. In MDA-MB-231 metastatic breast cancer 
cell line, CCN3 reorganizes the actin cytoskeleton and increases the cell trafficking 
by activating the GTPase Rac1 [23]. CCN3 was demonstrated to increase the bone 
metastasis in the studies conducted in metastatic breast cancer cell line [23]. This 
significant effect of CCN3 in metastasis was reported to deteriorate the osteoblast 
differentiation and provided a favorable environment for osteolytic breast cancer 
bone metastasis owing to supporting the osteoclastogenesis [23].
One of the overexpressed genes in bone-specific metastasis is the NAT1 
(N-acetyltransferase-1) and is a potential biological indicator for breast cancer.
3.3 Liver metastasis
The liver is the most common metastatic region for cancers and represents the 
second organ where breast cancer metastasis occurs. The development of liver 
metastasis in breast cancer patients is associated with Wnt signal and Ki67 signal 
independent of beta-catenin and an indicator of poor prognosis.
CXCR4 is the most common chemokine receptor that mediates the initiation 
of liver metastases. In addition, the dysregulation of cell adhesion molecules 
N-cadherin and E-cadherin was demonstrated to contribute to liver metastases in 
breast cancer (Figure 4). Breast cancer cells with higher N-cadherin level develop 
liver metastasis. E-cadherin which inhibits the metastasis was found lower in breast 
cancer cells with liver metastasis [24].
Although N-cadherin increases the liver metastasis, in normal conditions 
E-cadherin suppresses the development of liver metastasis. In addition, IL-6 
Figure 3. 
The molecular mechanisms that are mediated by the genes effective in breast cancer-associated bone metastasis.
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expression in liver metastasis of breast cancer facilitates the development of liver 
metastasis by inhibiting the E-cadherin expression [24].
Metastasis is a multistep procedure which is responsible for most cancer-asso-
ciated deaths and is affected by both cell-cell or cell-matrix interactions and tumor 
microenvironment (vascularization, etc.).
Clinically, low oxygen level (hypoxia) is known to be associated with metastasis 
[17]. Lysyl oxidase (LOX) expression is both associated with tumor suppression and 
tumor progression, and its role in tumorigenesis changes in accordance with the 
cellular location, cell type, and transformation. LOX expression is regulated by the 
hypoxia-inducible factor (HIF). Mostly distant metastasis is detected, and overall 
survival is poor in patients who have tumors which highly express the LOX. The 
LOX inhibition eliminates metastasis in breast cancer patients. LOX is required in 
metastatic growth to form a niche. LOX is required for hypoxia-associated metas-
tasis. Although LOX inhibition has no significant effect on primary tumor growth, 
LOX was associated to significantly decrease the lung metastases and inhibited the 
liver metastasis [25]. LOX molecule is suggested to be a good therapeutic target in 
prevention and elimination of metastasis [25].
3.4 Brain metastasis
Brain/CNS (central nervous system) metastasis develops in 10–30% of meta-
static breast cancer patients. Brain metastasis (BM) is detected as a complication 
that generally develops in the late stages of disease. Brain metastases develop after 
systemic emergence of metastases in the lungs, liver, and bone [26]. Two main 
primary tumors that do metastasis to the brain are lung and breast adenocarcino-
mas [18]. Brain metastases are associated with neurological disorders by affecting 
both the cognitive and sensory functions in addition to their association with highly 
poor prognosis.
Breast cancer is the most common cancer type where brain metastasis develops 
after lung metastasis. Lung and breast cancer-associated brain metastasis is more 
frequently detected than the primary brain tumors. Brain metastasis incidence 
has gradually been increasing in breast cancer patients. Due to the development 
of systemic therapies, many breast cancer patients live longer, but still in a way 
brain metastases may develop. Various factors were described for increased brain 
Figure 4. 
Regulation of cell adhesion molecules in liver metastasis with N-cadherin and E-cadherin.
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metastasis risk in breast cancer patients. These factors may be reported as early age, 
poorly differentiated tumor histology (high grade), hormone receptor negativity, 
and metastasis in more than four lymph nodes. These factors were associated with 
the brain metastasis risk [26]. HER2-positive and TNBC patients have a higher risk 
of brain metastasis than the luminal-type breast cancer patients. Brain metastasis is 
detected in 30–40% of HER2-positive and triple negative breast cancer patients [26]. 
Brain metastasis in lung cancer generally develops within 2 years after the diagnosis 
of primary lung cancer, and brain metastasis in breast cancer is generally associated 
with the metastatic stage of the disease and develops 10 years after the primary 
diagnosis and after a successful treatment. However, brain metastasis in triple 
negative breast cancer patients develops in earlier periods. The development of brain 
metastasis in breast cancer was detected to be associated with Wnt, Notch, and EGFR 
pathways [27]. CXCL12 that is expressed in the brain and CXCR4 receptor located in 
the surface of the breast tumor cells block the cell signaling pathway together with 
CXCR4 in brain metastasis. Breast cancer-associated brain metastasis generally devel-
ops in ~20–30% of breast cancer patients. Breast cancer-associated metastasis shows 
poor prognosis due to the lack of molecular therapeutic targets. The rate of detection 
of brain metastasis in HER2+ and triple negative breast cancer subtypes is 20–50%.
HER2 amplifications and mutations were frequently demonstrated in breast 
cancer and in breast cancers with brain metastasis [27]. There are no target-specific 
treatment options in the clinical practice generally in breast cancers that carry 
BRCA1 and BRCA2 gene mutation and triple negative brain metastasis. New 
molecular targets HER2, EGFR, VEGFR, PARP, mTOR, and CDK-4/6 were discov-
ered in the treatment of breast cancer with metastasis to the brain.
Brain metastasis is a multistep procedure with migration, intravasation, cir-
culation, adhesion, extravasation, and brain microenvironment. Particularly the 
blood-brain barrier (BBB) is highly selective in the entrance of tumor cells and 
therapeutics to the brain microenvironment. In compliance with that, the cells to 
make a metastatic lesion in the brain have a specific clonal origin. This shows that 
a brain metastasis shared the common abnormalities with a metastasis ancestor 
cell, and the further abnormalities could only be present in only brain metastatic 
subclones. More frequent detection of TP53 mutations in breast cancer with brain 
metastasis compared with the other breast cancers is an example. COX2, EGFR, and 
HBEGF were described as the extravasation stimulating factors through coloniza-
tion in breast cancers with metastases to the brain and lung. The higher expression 
of the genes CXCR4, PLLP, TNFSF4, VCAM1, SLC8A2, and SLC7A11 facilitates 
the development of brain metastases. In addition, the majority of snoRNAs and 
snRNAs have higher expression in breast cancer metastasizing to the brain [28].
3.5 Lung metastasis
Luminal breast tumors have the tendency to do metastasis to the bone; however, 
basal-like breast tumors mainly do metastasis to the lungs. The genes that are 
effective in the emergence of lung metastasis are generally associated with poor 
prognosis [29]. An epidermal growth factor receptor-ligand epiregulin (EPR) and 
the genes such as COX2, MMP-1, and MMP-2 affect the tumor angiogenesis and 
facilitate the lung metastasis by reaching to the lung capillary vessels. The inhibition 
of EGFR and COX2 minimizes the lung metastasis [30]. Protein deacetylase SIRT7 
was demonstrated to inhibit the development of lung metastasis of breast cancer 
cells by antagonizing the TGF-β signal [31]. An increased expression was reported 
in the genes DSC2, TFCP2L1, UGT8, ITGB8, ANP32E, and FERMT1 that are associ-
ated with cell involvement and signal transduction in patients with lung metastasis 
of breast cancer [31].
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Other genes except PTEN were detected to be overexpressed in the studies 
investigating the mechanism of lung metastasis. Although none of the described 
genes were found to be associated with previous metastasis, some of the encoded 
molecules were detected to have significant roles in the acquisition of proliferative 
and invasive characteristics to epithelial cells. The regulation of the epithelial-
mesenchymal transition (EMT) is highly important in metastatic process. Integrins 
regulate the EMT by mediating the TGF-β signal activation [32]. FERMT1 gene is 
known to be an effective gene in TGF-mediated epithelial-mesenchymal transition. 
Therefore, FERMT1 gene is suggested to be associated with lung metastasis.
The decrease of the expression of a tumor suppressor gene PTEN was found to 
be associated with lung metastasis in a study [33]. PTEN is one of the main mole-
cules which regulates the signaling pathways associated with reproduction, growth, 
cell viability, and cell migration and was detected to mutate in various different 
tumors. In addition, PTEN regulates the EMT in lung metastasis by affecting the 
cell viability and CXCR4 chemotaxis. The biological indicators EGFR and FOXC1 
were demonstrated to be associated with each other and controlled the lung metas-
tasis in breast cancer [33]. The survival rate of breast cancer patients with lung 
metastasis is very low despite the treatment options as chemotherapy, radiotherapy, 
and target-specific treatment against lung metastasis. Therefore, the development 
of new therapeutic strategies is significantly important for understanding the 
underlying mechanisms in lung metastasis.
A Notch signaling pathway receptor Notch-1 was demonstrated to have a criti-
cal role in cell renewal, reproduction, and apoptosis of BCSC by regulating the 
epithelial-mesenchymal transition in breast cancer [34]. The abnormal activation 
of notch signaling pathway contributes to the breast cancer metastasis by primarily 
regulating the EMT and angiogenesis.
Wnt/β-catenin signaling has a significant role in the embryonic induction and 
tumorigenesis of the breast gland [35]. The nuclear localization and overexpression 
of β-catenin are an indicator of Wnt/β-catenin signal activation. Various clinical and 
laboratory studies showed that the abnormal activation of Wnt/β-catenin signaling 
was associated with poor prognosis in breast cancer patients and mainly increased 
in triple negative cancer subtype [36]. In addition, the Wnt-helper receptor LRP6 
was commonly overexpressed in highly aggressive triple negative breast cancer. 
Wnt/β-catenin signaling pathway contributes to the EMT and breast cancer metas-
tases in addition to controlling the cell proliferation in breast cancer (Table 1).
Hedgehog (Hg) signaling pathway has a significant role in the development of 
ducts of the breast. In addition, Hg regulates the breast cancer stem cells and has a 
significant role in cancerogenesis [37]. Hg proteins regulate the breast cancer cell 
migration. Hg, Notch, and Wnt signaling pathways demonstrate joint behavior 
in tumor development and metastasis in cancer. These signaling pathways have 
significant roles in the development of breast cancer and lung metastasis.
Notch pathway Wnt pathway Hedgehog 
pathway
Uncontrolled growth The self-renewal of breast cancer stem cells TGF-β
The self-renewal of breast cancer stem cells EMT CXCL12-CXC4
Angiogenesis, EMT
Formation of lung niches
Development of lung metastasis
Table 1. 
The functioning of signaling pathways in breast cancer-associated lung metastasis.
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Breast cancer is characterized with a separate metastatic pattern including the 
regional lymph nodes, bone marrow, lung, and liver. Chemokines are a group of 
small-molecular-weight protein which bind to chemokine receptors attached to G 
protein. Chemokines have a significant role in various pathological conditions such as 
cell migration, development, and inflammation. Binding of chemokines to receptors 
causes a structural change which activates the signaling pathways and promotes the 
migration. Chemokine and chemokine receptors have a critical role in identification of 
metastatic targets of tumor cells. Chemokines are divided into two groups in accor-
dance with their functions as inflammatory chemokines and homeostatic chemokines. 
Inflammatory chemokines are induced by inflammation, and homeostatic chemokines 
are structurally expressed and have a role in homeostatic immune regulation [38].
Chemokines have a significant role in the progression of cancers [38] and have 
functions in tumoral growth, aging, angiogenesis epithelial-mesenchymal transi-
tion, and metastasis. The expression of chemokines and their receptors changes 
in malignity and then causes abnormal chemokine receptor signaling. This change 
stems from the inactivation of the tumor-suppressive genes or from the structural 
activation of oncogenes that have a role in the regulation of chemokines [38].
Chemokine receptors CXCR4 and CCR7 are highly expressed in human breast 
cancer cells, malignant breast tumors, and metastases [38]. In breast cancer cells, 
CXCR4 or CCR7 signaling mediates the actin polymerization and pseudopodia and 
then induces the chemotaxis and invasion.
The in vivo inactivation of CXCL12/CXCR4 interactions significantly inhibits 
the metastasis of breast cancer cells to the regional lymph nodes and lungs [38]. 
CXCL12/CXCR4 interactions also cause bone marrow metastasis of breast cancer cells.
Tumor cell migration and metastasis have various similarities with the leukocyte 
trafficking that are regulated by chemokines and their receptors. Cell trafficking-
associated ligands CXCL12/SDF-1α and CCL21/6Ckine are highly expressed in the 
organs representing the first targets of metastatic breast cancer [38]. Malignant 
melanoma which has high skin metastasis and has a similar metastatic characteristic 
with breast cancer has high CCR10 expression in addition to CXCR4 and CCR7 [38]. 
Therefore, both CXCR4 and CCR7 are highly critical molecules for cell trafficking 
and tissue homeostasis.
CXCL12 is the only ligand known for CXCR4. Metastatic breast cancers were 
demonstrated to selectively express CXCR4 and migrated to organs which highly 
express the ligand CXCL12 that is also known as SDF-1 [38]. CXCR4 expression is 
known to be higher in malignant breast tumors than the levels in healthy breast 
tissues. CXCL12 was highly expressed in organs such as the lung, bone, liver, and 
lymph nodes where the breast cancer cells preferred to do metastasis [38]. This 
showed that metastatic breast tumor cells selectively expressed CXCR4, and thus 
breast cancer cells which reached to organs have high CXCL12 expression levels. In 
addition, the in vivo inhibition of CXCR4-CXCL12 interactions was demonstrated 
to significantly decrease the metastasis of breast tumor cells to the lymph node and 
lungs [38]. Therefore, CXCL12-CXCR4 signaling is suggested to be an important 
therapeutic target for metastatic breast cancer treatment.
CXCR4-CXCL12 receptor-ligand interactions in breast cancer allow the invading 
of tumor cells of neighboring tissues and for successful metastasis. The receptor-
ligand interaction triggers the actin polymerization and facilitates the formation of 
pseudopodia. Thus, the invading of breast tumor cells of the neighboring tissues 
or distant tissue is induced or facilitated [39]. Chemokine CXCL12 activates the 
chemokine receptor CXCR4 in endothelial cell which supports the endothelial cell 
migration and growth [39]. The high expression of CXCL12 in the lung, liver, and 
lymph nodes showed that these chemokines have a role in the metastasis of breast 
cancer cells for these anatomic regions.
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CCL21 and its receptor CCR7 have critical importance in the settlement of lym-
phocytes to secondary lymphoid organs. The primary breast cancer cells in lymph 
nodes and most metastatic cancer cells express CCR7, and there is an association 
between CCR7 expression and lymph node metastasis. In addition, higher CCR7 
expression was demonstrated to be associated with poor prognosis and shorter 
survival [38].
Extracellular matrix (ECM) proteins tenascin-C (TNC), periostin (POSTN), 
and versican (VCAN) are highly important molecules in the formation of metastasis 
and have a critical role in the formation of breast cancer colonization in the lung 
tissue that has a tendency for metastasis. Tenascin-C, which is normally produced 
by fibroblasts, is also secreted by breast cancer stem cells. This abnormal expression 
of tenascin-C by breast cancer stem cells forms a niche in lung colonization and 
creates a metastasis-initiating effect. Periostin is a stromal factor that may bind to 
Wnt ligands and is effective in breast cancer metastasis [40].
Cancer-associated fibroblasts (CAFs) have a significant role in breast cancer 
metastasis by expressing the Tiam1 and osteopontin in breast cancer tissue [40]. 
In addition, the expression of a CAF-associated protein thrombocyte-associated 
growth factor receptor (PDGFRβ) is highly associated with lung metastasis in 
breast cancer. In addition, CAFs increase the primary tumor growth through 
TGF-β and contribute to the development of lung metastasis-associated fibrous 
tissue in breast cancer [41]. Therefore, CAF is suggested to be a potential anti-
cancer therapeutic target. The development of strategies targeting the micro-
environment may be effective in the treatment or inhibition of breast cancer 
metastasis.
Because the lungs have a unique histological feature, cancer cell meets with high 
interstitial fluid pressure and thus supports the PDGFRβ expression when a cancer 
cell does metastasis to a small interstitial tissue between the alveoles. Lung metasta-
sis is known to be associated with triple negative breast cancer.
As conclusion, the expression changes in these genes in breast cancer cells 
may be detected in bone, lung, brain, liver, and lymph node metastases. The 
studies revealed that there were important differences in metastatic behavior 
between breast cancer subtypes (Table 2). Therefore, the treatment of meta-
static breast cancer must be performed by targeting the organ with metastasis, 
and the development of target molecules will form the future treatment 
protocols.
Luminal B, HER2+/ER/PR+ and HER2+/ER/PR, tumors do more metastasis 
to the brain, liver, lung, and bone than the luminal A tumors. Basal-like tumors 
do higher rates of brain and lung metastases. As demonstrated in Table 2, breast 
cancer cells do metastasis to the lung through triple negative breast cancer, basal, 
luminal B, HER2 molecular subtypes, the genes activated by growth factor recep-
tors, matrix metalloproteinases, and the pathways of COX2 and LOX2 genes. Breast 
cancer cells with HER2+, luminal-HER2, triple negative breast cancer, and basal 
histologies primarily have a tendency to do metastasis to the brain. These molecular 
subtypes do metastasis to the brain with the effect of genes activated by growth 
factor receptors, matrix metalloproteinases, COX2, and chemokinesis. Clarifying 
the association of these signalings and genes with molecular subtypes suggests the 
significant new therapeutic targets for metastatic breast cancer treatment. The 
bone metastasis of luminal and HER2 breast cancer molecular subtypes is caused 
by growth factor genes and interleukins. Chemokine and integrin molecules that 
cause liver metastasis are more frequently detected in HER2+, ER+, luminal B, and 
luminal-HER2 molecular subtypes. BCR pathway proteins and CCN proteins, the 
genes responsible in Hg signaling pathway, cause lymph node metastasis in luminal 
type and HER2+ molecular subtypes [1].
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Individualized target-specific appropriate treatment methods will be developed 
for metastatic breast cancer owing to the knowledge of the association of genes 
with each other that cause metastasis and the follow-up of the pathways where 
these genes gained function. There is an association between genomic differences 
and various gene expressions that cause poor prognosis in breast cancer. The gene 
expression profiles of primary tumors must be compared and associated with 
metastasis for describing and clarifying the tumor factors of metastatic breast can-
cer. The better understanding of the functioning of these genes will help to develop 
specific therapeutic approaches for metastatic breast cancer.
The molecules and genes on the pathways will be used in the diagnosis, prog-
nosis and treatment response of metastatic breast cancer in the future. These 
effective molecules will be used as a tumor-specific indicator, and also detected 
in different biological materials like tissue, saliva, blood, serum, and urine in 
metastatic breast cancer. In addition, these genes may be used as therapeutic 
targets. The inactivation of these genes by inhibition or with biological antibodies 
through apoptosis is significantly important to resolve the tumor and metastasis. 
Different therapeutic strategies will be developed, and these molecules will be 
used in individualized treatment for inhibiting the tumor metastasis considering 
the associations between these genes, and chemokines, and integrins. The breast 
cancer molecular subtypes will be treated, and a progress will be enabled in the 
treatment of metastatic breast cancer with the development of molecular drugs 
which inhibit the active pathways or eliminate the pathway transition of the genes 
effective in metastatic breast cancer.
Tissue Lung Brain Bone Liver Lymph node
Molecular 
subtypes 
of breast 
cancer
TNBC
Basal
Luminal B
HER2+
HER2+
Luminal-HER2
TNBC
Basal
Luminal 
HER2
HER2+
ER+
Luminal B
Luminal-HER2
Luminal
HER2+
Molecular 
pathways 
and genes
Growth factors
TGF-β
EGFR
VEGF
Matrix
Metalloproteinases
MMP-1
MMP-2
Chemokines
CXCL12
CXCR4
BMP inhibitors
Other factors
COX-2
LOX
Growth factors
VEGF
HBEGF
Matrix
Metalloproteinases
MMP-9
MMP-1
Chemokines
CXCR4
CXCL12
CCR7
CCL21
Cytokines
CK5
Notch pathways
Wnt pathways
Hg pathways
Other factors
COX-2
LOX
IL-8
COX-2
ICAM1
PTEN
CAF
Growth 
factors
IGF1
PGE2
TGF-β
Other 
factors
PDGF
FGF2
IL11
IL-6
IL-1
OPN
Chemokines
CXCR4
CXCL12
CCR7
CCL21
Other factors
IL-6
N-cadherin
E-cadherin
LOX
OPN
VEGF
TWIST
WNT pathway
ECM
CCN proteins
BCR 
pathways
Hedgehog 
(Hg) 
pathway
Table 2. 
The organ-specific genes and signaling pathways effective in metastatic breast cancer.
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